Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Ablation + Chemo in Pancreatic Cancer Liver Metastasis
NCT04420130Phase 2Withdrawn
- Start
- Aug 2020
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab in pancreatic cancer (PC). Planned start Aug 2020; status: withdrawn.
02
Drugs
camrelizumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04420130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04420130.